Hippocampus-Sparing Radiation and Chemotherapy

Before Radiation Therapy Oncology Group (RTOG) protocol 9802, when there was no survival advantage associated with receipt of radiation therapy (European Organization for Research and Treatment of Cancer [EORTC] 22845), the debate regarding whether to treat with radiation therapy centered on which would lead to worse neurocognition and quality of life: progression of a patient's residual tumor or radiation side effects. Because the patient is high risk by EORTC criteria with a median survival of 3.5 years, we would have recommended radiation, because the potential late neurocognitive side effects of radiation are unfortunately less of a concern (1).

https://ift.tt/2IYdwDT